ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Adicet Bio Inc

Adicet Bio Inc (ACET)

2.00
0.05
(2.56%)
Closed April 22 4:00PM
2.1419
0.1419
(7.09%)
After Hours: 7:58PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.1419
Bid
2.01
Ask
2.25
Volume
325,351
1.955 Day's Range 2.045
1.10 52 Week Range 7.50
Market Cap
Previous Close
1.95
Open
2.00
Last Trade Time
Financial Volume
$ 649,140
VWAP
1.9952
Average Volume (3m)
1,450,493
Shares Outstanding
43,164,522
Dividend Yield
-
PE Ratio
-0.69
Earnings Per Share (EPS)
-3.31
Revenue
-
Net Profit
-142.66M

About Adicet Bio Inc

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like ant... Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Adicet Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ACET. The last closing price for Adicet Bio was $1.95. Over the last year, Adicet Bio shares have traded in a share price range of $ 1.10 to $ 7.50.

Adicet Bio currently has 43,164,522 shares outstanding. The market capitalization of Adicet Bio is $98.42 million. Adicet Bio has a price to earnings ratio (PE ratio) of -0.69.

ACET Latest News

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience...

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Expanded clinical pipeline into autoimmune diseases with U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug Application (IND) for ADI-001; initiation of Phase 1...

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0181-0.8379629629632.162.351.96171242.10499606CS
4-0.0181-0.8379629629632.162.431.96259692.23233179CS
12-0.5181-19.4774436092.663.621.8814504932.56746686CS
260.621940.91447368421.523.771.111277232.47157499CS
52-4.0481-65.39741518586.197.51.18951642.66410896CS
156-10.7581-83.39612403112.921.871.16481168.24060246CS
260-12.8381-85.701602136214.9821.871.15616588.45066223CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MTTRMatterport Inc
$ 4.785
(175.00%)
72.29M
AGBAAGBA Group Holding Ltd
$ 2.52
(101.60%)
211.85M
MLECMoolec Science SA
$ 2.443
(74.50%)
79.68M
NIVFNewGenIvf Group Ltd
$ 1.30
(68.83%)
80.5M
EDBLEdible Garden AG Inc
$ 6.26
(66.49%)
16.04M
VAXXVaxxinity Inc
$ 0.2636
(-44.63%)
5.86M
IKTInhibikase Therapeutics Inc
$ 1.37
(-32.84%)
369.21k
TWGTop Wealth Group Holding Ltd
$ 2.55
(-31.64%)
2.56M
BPTHBio Path Holdings Inc
$ 2.96
(-31.00%)
869.6k
TELOTelomir Pharmaceuticals Inc
$ 5.6001
(-29.87%)
134.23k
AGBAAGBA Group Holding Ltd
$ 2.52
(101.60%)
211.85M
SQQQProShares UltraPro Short QQQ
$ 12.47
(-2.88%)
157.15M
TSLATesla Inc
$ 142.05
(-3.40%)
107.15M
JAGXJaguar Health Inc
$ 0.1798
(14.60%)
106.88M
NIVFNewGenIvf Group Ltd
$ 1.30
(68.83%)
80.5M

ACET Discussion

View Posts
Monksdream Monksdream 7 months ago
ACET new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
ACET new 52 week
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
ACET new 52 week low
πŸ‘οΈ0
jondoeuk jondoeuk 7 months ago
Upcoming https://www.businesswire.com/news/home/20230927031162/en/Adicet-Bio-to-Present-Three-Scientific-Posters-Highlighting-its-Allogeneic-Gamma-Delta-T-Cell-Platform-and-Programs-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting
πŸ‘οΈ0
jondoeuk jondoeuk 10 months ago
Durability was always the big question for $ACET. Yesterday's dataset vs #ASH22 above https://t.co/PNIL1N2eUF— Jacob Plieth (@JacobPlieth) June 27, 2023
πŸ‘οΈ0
masterofdisaster masterofdisaster 2 years ago
No sell off...guess I bet wrong
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
Phase 1's usually suck wind, I lost $80K on another one,

BIG lesson learned


πŸ‘οΈ0
masterofdisaster masterofdisaster 2 years ago
It was weird....I think the MMs drop this at open to begin the sell off today.
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
whats weird is the rally after the offering


this market is upside down

topsy turvey

πŸ‘οΈ0
masterofdisaster masterofdisaster 2 years ago
Bought puts today anticipating an offering and there it is.
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
13.20 low start

ACET
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
14.20 in AH. Nice day for the clinical FDA phase I trial results.
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
thanks for creating the board

I was too lazy, did I say lazy, I meant bizy

https://ih.advfn.com/stock-market/NASDAQ/adicet-bio-ACET/stock-news/86734727/adicet-posts-early-stage-data-for-off-the-shelf-ca
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Adicet Bio shares are trading higher after the company announced interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001.
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Adicet Bio Inc. is a biotechnology company that is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and hematological indications.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock